Paying for Cures Workshop

Survey the financial challenges of sustaining new cell and gene therapies, assess adoption barriers, and anticipate coming changes in policy and practice

Image

Paying for Cures Workshop

Survey the financial challenges of sustaining new cell and gene therapies, assess adoption barriers, and anticipate coming changes in policy and practice

Durable, potentially curative therapies for genetic disorders and cancer have arrived. Short—even single dose—treatment regimens yield lasting health benefits, but large single payments will challenge the current reimbursement system. Policy, regulations, and business operations need to evolve to enable emerging solutions.

August 7 
Massachusetts Institute of Technology

Cambridge, Massachusetts

SOLD OUT

This intensive 1-day workshop at MIT will include: 

  • An overview of cell and gene therapies’ unique and challenging characteristics
  • Insights on the financial issues and impacts of performance-based agreements for new therapies
  • A discussion of evolving policy and legislative changes
  • Interaction with sector thought leaders and MIT researchers

This interactive workshop
is ideal for:

  • Healthcare policy consultants and analysts
  • Industry / trade group strategists
  • Academic researchers
  • Patient advocates

Hosted by MIT Center for Biomedical Innovation NEWDIGS Initiative

ImageImageImage

Agenda

Introduction: Therapies, stakeholder perspectives, and concerns
Mark Trusheim (MIT), Michelle Harika (Equity Healthcare)
Drug Development Pipeline
Colin Young (MIT)
Precision Financing Promises and Challenges
Mark Trusheim (MIT)
Impacts of current policy on performance based agreements
Daniel Mytelka (MIT)
Panel & Discussion

Barriers & Obstacles
Daniel Mytelka (MIT, Moderator), Diane Berry (Sarepta), Kaha Hizanishvili (MassHealth), Brendan Hayes (National Hemophilia Foundation), Desiree Otenti (Blue Cross Blue Shield of Massachusetts)

Insider View from Capitol Hill

Jeff Lucas, Policy Advisor, Office of Senator Bill Cassidy

Panel & Discussion

Proposed legislation changes review and discussion
Brian Carey (Foley Hoag, Moderator), Rob Falb (Alliance for Regenerative Medicine), Michael Sherman (Harvard Pilgrim Healthcare), Kristin Wolff (bluebirdbio), John Martin (CRISPR Therapeutics)

Fireside chat: Fair provider payments
Michael Ciarametaro (National Pharmaceutical Council), Krishna Komanduri (University of Miami Health System), Edward Abrahams (Personalized Medicine Coalition)
Recap and conclusion
Mark Trusheim (MIT)

Registration

SOLD OUT

August 7
8am – 4:30pm

Samberg Conference Center, 7th Floor
Massachusetts Institute of Technology
50 Memorial Drive
Cambridge, MA 02142

Registration fees

Standard individual:
$1,800

Standard group (2+ people):
$1500 per person

Nonprofit / Academic / Public individual:
$900

Nonprofit / Academic / Public group (2+ people):
$750 per person

50% discount for FoCUS Project Sponsors. Please contact Katie Torrence to get the code for automatic discount at registration.